Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 689-700

  Romano, Alessandra ^a,b,c   Parrinello, Nunziatina Laura ^a,c   Vetro, Calogero ^a,c   Forte, Stefano ^d   Chiarenza, Annalisa ^c   Figuera, Amalia ^c   Motta, Giovanna ^c   Palumbo, Giuseppe Alberto ^c   Ippolito, Massimo ^e   Consoli, Ugo ^f   Raimondo, Francesco Di ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Fondazione Veronesi   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d IOM Ricerca srl   (Italy)

^e CANNIZZARO HOSPITAL   (Italy)

^f ARNAS Garibaldi   (Italy)

Author keywords

Hodgkin lymphoma; Myeloid derived suppressor cells; Positron emission tomography 2

Indexed keywords

BLEOMYCIN; C REACTIVE PROTEIN; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; FLUORODEOXYGLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CD34 SELECTION; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ENDOMETRIOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTRITIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REFRACTORY PERIOD; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SUPPRESSOR CELL; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; BLOOD; BONE MARROW CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RADIOGRAPHY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELOID CELLS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84922778516     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13198     Document Type: Article

References (46)

1. Avigdor, A., Bulvik, S., Levi, I., Dann, E.J., Shemtov, N., Perez-Avraham, G., Shimoni, A., Nagler, A., Ben-Bassat, I. & Polliack, A. (2010) Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Annals of Oncology, 21, 126-132.
2. Bauer, K., Skoetz, N., Monsef, I., Engert, A. & Brillant, C. (2011) Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Systematic Review, CD007941.
3. Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series, B 1, 289-300.
4. Benjamini, Y. & Yekutieli, D. (2001) The control of the false discovery rate in multiple testing under dependency. Annals of Statistics, 29, 1165-1188.
5. Bennett, M.H., MacLennan, K.A., Easterling, M.J., Vaughan Hudson, B., Jelliffe, A.M. & Vaughan Hudson, G. (1983) The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clinical Radiology, 34, 497-501.
6. van den Berg, A., Visser, L. & Poppema, S. (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. American Journal of Pathology, 154, 1685-1691.
7. Brimnes, M.K., Vangsted, A.J., Knudsen, L.M., Gimsing, P., Gang, A.O., Johnsen, H.E. & Svane, I.M. (2010) Increased level of both CD4 + FOXP3 + regulatory T cells and CD14 + HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scandinavian Journal of Immunology, 72, 540-547.
8. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
9. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
10. Condamine, T. & Gabrilovich, D.I. (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends in Immunology, 32, 19-25.
11. Deau, B., Bachy, E., Ribrag, V., Delarue, R., Rubio, M.T., Bosq, J., Varet, B., Brousse, N., Hermine, O. & Canioni, D. (2013) Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leukaemia & Lymphoma, 54, 41-45.
12. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.K., Dühmke, E., Loeffler, M. & Group, G.H.s.L.S. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
13. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.K., Hasenclever, D. & Löffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
14. Follmann, D.A. & Proschan, M.A. (1999) A multivariate test of interaction for use in clinical trials. Biometrics, 55, 1151-1155.
15. Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12, 253-268.
16. Gallamini, A. (2010) Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica, 95, 1046-1048.
17. Gallamini, A. & Kostakoglu, L. (2012) Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt? Haematologica, 97, 797-799.
18. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
19. Gallamini, A., Patti, C., Viviani, S., Rossi, A., Fiore, F., Di Raimondo, F., Cantonetti, M., Stelitano, C., Feldman, T., Gavarotti, P., Sorasio, R., Mulè, A., Leone, M., Rambaldi, A., Biggi, A., Barrington, S., Fallanca, F., Ficola, U., Chauvie, S., Gianni, A.M. & Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. British Journal of Haematology, 152, 551-560.
20. Gallamini, A., Di Raimondo, F., La Nasa, G., Romano, A., Borra, A. & Greco, M. (2013) Standard therapies versus novel therapies in Hodgkin lymphoma. Immunology Letters, 155, 56-59.
21. Greaves, P., Clear, A., Coutinho, R., Wilson, A., Matthews, J., Owen, A., Shanyinde, M., Lister, T.A., Calaminici, M. & Gribben, J.G. (2013) Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. Journal of Clinical Oncology, 31, 256-262.
22. Harris, J.A., Jain, S., Ren, Q., Zarineh, A., Liu, C. & Ibrahim, S. (2012) CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagnostic Pathology, 7, 12.
23. Kamper, P., Bendix, K., Hamilton-Dutoit, S., Honore, B., Nyengaard, J.R. & d'Amore, F. (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica, 96, 269-276.
24. Kotsakis, A., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A. & Whiteside, T.L. (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. Journal of Immunological Methods, 381, 14-22.
25. Kusmartsev, S., Nagaraj, S. & Gabrilovich, D.I. (2005) Tumor-associated CD8 + T cell tolerance induced by bone marrow-derived immature myeloid cells. Journal of Immunology, 175, 4583-4592.
26. Montes-Moreno, S. (2011) Hodgkin's lymphomas: a tumor recognized by Its microenvironment. Advances in Hematology, 2011, 142395.
27. Nagaraj, S., Collazo, M., Corzo, C.A., Youn, J.I., Ortiz, M., Quiceno, D. & Gabrilovich, D.I. (2009) Regulatory myeloid suppressor cells in health and disease. Cancer Research, 69, 7503-7506.
28. Nagaraj, S., Youn, J.I., Weber, H., Iclozan, C., Lu, L., Cotter, M.J., Meyer, C., Becerra, C.R., Fishman, M., Antonia, S., Sporn, M.B., Liby, K.T., Rawal, B., Lee, J.H. & Gabrilovich, D.I. (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research, 16, 1812-1823.
29. Pak, A.S., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G.J. & Young, M.R. (1995) Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Research, 1, 95-103.
30. Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. (2005) Global Cancer Statistics 2002. CA: a Cancer Journal for Clinicians, 55, 74-108.
31. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S. & Bronte, V. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology, 22, 238-244.
32. Porrata, L.F., Ristow, K., Colgan, J.P., Habermann, T.M., Witzig, T.E., Inwards, D.J., Ansell, S.M., Micallef, I.N., Johnston, P.B., Nowakowski, G.S., Thompson, C. & Markovic, S.N. (2012) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica, 97, 262-269.
33. Porrata, L.F., Ristow, K.M., Habermann, T.M., Macon, W.R., Witzig, T.E., Colgan, J.P., Inwards, D.J., Ansell, S.M., Micallef, I.N., Johnston, P.B., Nowakowski, G., Thompson, C.A. & Markovic, S.N. (2013) Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer Journal, 3, e110.
34. Romano, A., Vetro, C. & Adriani, M. (2011) Advances in understanding regulatory myeloid cells. Cancer Biology & Therapy, 11, 923-926.
35. Romano, A., Vetro, C., Donnarumma, D., Forte, S., Ippolito, M. & Di Raimondo, F. (2012) Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma. Haematologica, 97, e21-e23; author reply e24.
36. Sánchez-Aguilera, A., Montalbán, C., de la Cueva, P., Sánchez-Verde, L., Morente, M.M., García-Cosío, M., García-Laraña, J., Bellas, C., Provencio, M., Romagosa, V., de Sevilla, A.F., Menárguez, J., Sabín, P., Mestre, M.J., Méndez, M., Fresno, M.F., Nicolás, C., Piris, M.A., García, J.F. & Spanish Hodgkin Lymphoma Study Group. (2006) Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood, 108, 662-668.
37. Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., Young, L.S. & Niedobitek, G. (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematological Oncology, 27, 31-39.
38. Serafini, P., Carbley, R., Noonan, K.A., Tan, G., Bronte, V. & Borrello, I. (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research, 64, 6337-6343.
39. Serafini, P., Borrello, I. & Bronte, V. (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, England 16, 53-65.
40. Shojaei, F., Wu, X., Malik, A.K., Zhong, C., Baldwin, M.E., Schanz, S., Fuh, G., Gerber, H.P. & Ferrara, N. (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1 + myeloid cells. Nature Biotechnology, 25, 911-920.
41. Shuster, J.J. (1991) Median follow-up in clinical trials. Journal of Clinical Oncology, 9, 191-192.
42. Skoetz, N., Trelle, S., Rancea, M., Haverkamp, H., Diehl, V., Engert, A. & Borchmann, P. (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet Oncology, 14, 943-952.
43. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C. & Gascoyne, R.D. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New England Journal of Medicine, 362, 875-885.
44. Steidl, C., Connors, J.M. & Gascoyne, R.D. (2011a) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology, 29, 1812-1826.
45. Steidl, C., Farinha, P. & Gascoyne, R.D.. (2011b) Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica, Italy 96, 186-189.
46. Talmadge, J.E. & Gabrilovich, D.I. (2013) History of myeloid-derived suppressor cells. Nature Reviews Cancer, 13, 739-752.